English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Reumatologia 2013; 51/1 Summary The objective of the study was to investigate the effects and safety of adalimumab (ADA) therapy in the national therapeutic pro gramme, in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Material and methods: The process of ADA therapy was analysed in 41 patients (24 RA, 11 AS, 6 PsA). Patients were qualified, according to the rules of the therapeutic programme of the National Health Serv ice, due to high disease activity, despite previous treatment. Moni toring of patients was performed according to the requirements of the therapeutic programme. ADA was given subcutaneously 40 mg every other week. Results: In the RA group, an adequate response to therapy was observed in 13 patients (54.2%): remission in 8 (33.3%) and low disease activ ity in 5 (20.9%), which continued in 5 patients after ADA cessation, for a mean of 4.5 months. Primary inefficacy after 3 months of ther apy (lack of adequate response) was observed in 4 (16.7%), after 6 months of therapy (lack of remission/low disease activity) in 10 (41.7%). During remission/low activity period, exacerbation of RA was observed in 6/13 patients; in 2/13 secondary inefficacy was observed. In the AS group, in 1 patient (9.1%) primary inefficacy was observed. In 10 (90.9%) low disease activity was achieved in 9 patients (90.9%), which continued for a mean of 5.4 months. During the improvement period, after cessation of ADA, 8/10 patients experienced exacerba tion; secondary inefficacy was observed in 1/10 patients. In the PsA group, low disease activity was achieved in 5 patients (83.3%) during ADA administration; in 1 (16.7%) primary inefficacy was observed. In

reumatologia

Adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in therapeutic programmes – personal experience